Clinical Trial
Accepted on 03 Mar 2026
Fractional BNT162b2 boosters induce durable immune responses after non-mRNA priming in Mongolia: a randomised controlled trial
in Vaccines and Molecular Therapeutics
Clinical Trial
Accepted on 03 Mar 2026
in Vaccines and Molecular Therapeutics
Original Research
Accepted on 03 Mar 2026
in Microbe and Virus Interactions with Plants
Original Research
Accepted on 03 Mar 2026
in Immunological Tolerance and Regulation
Opinion
Accepted on 03 Mar 2026
in Vaccines and Molecular Therapeutics
Original Research
Accepted on 03 Mar 2026
in Optimization
Original Research
Accepted on 03 Mar 2026
in Educational Psychology
Original Research
Accepted on 03 Mar 2026
in Nature-Based Solutions
Case Report
Accepted on 03 Mar 2026
in Orthopedic Surgery
Original Research
Accepted on 03 Mar 2026
in Terrestrial Microbiology
Review
Accepted on 03 Mar 2026
in Molecular and Cellular Oncology
Hypothesis and Theory
Accepted on 03 Mar 2026
in Regulatory Toxicology
Original Research
Accepted on 03 Mar 2026
in Clinical and Translational Cardiovascular Medicine
Original Research
Accepted on 03 Mar 2026
in Cancer Genetics
Original Research
Accepted on 03 Mar 2026
in Atherosclerosis and Vascular Medicine
Original Research
Accepted on 03 Mar 2026
in Veterinary Infectious Diseases
Original Research
Accepted on 03 Mar 2026
in Educational Psychology